Oral medicine to slow damage from pulmonary arterial hypertension
Official title: Development of a novel disease modifying oral therapy for pulmonary arterial hypertension.
Funded at Vasculonics, LLC · NIH-11193989 · Data updated 2026-11-12
A new oral drug called VN-1032 aims to slow blood-vessel damage in people with pulmonary arterial hypertension.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vasculonics, LLC NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project start | August 23, 2019 |
| Project end | August 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $1,276,514 |
| NIH project number | 5R44HL149496-03 |
| Project ID | NIH-11193989 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be adults diagnosed with pulmonary arterial hypertension, especially those with progressive disease despite current vasodilator treatments.
✕Less likely to help
People with pulmonary hypertension caused by left-heart disease or lung disease, or anyone without PAH, are unlikely to benefit from this therapy.
What this research studies
This project is developing VN-1032, an oral medicine designed to change the course of pulmonary arterial hypertension by targeting the AhR pathway and lowering ADMA, two drivers of blood-vessel injury. The team has optimized the chemical and seen promising results in laboratory and animal models that mimic human PAH. Ongoing work focuses on final preclinical testing to support future human studies and regulatory steps. If you have PAH, this work is intended to move beyond symptom relief toward treatments that address the underlying vascular disease.
Why it matters
Potential benefit: If successful, VN-1032 could slow or stop PAH progression and potentially improve survival beyond current symptom-focused therapies.
How similar studies have gone: Targeting the AhR and ADMA pathways for PAH is relatively new: preclinical studies show promise but no approved therapies yet use this approach.
Where this research is happening
-
Vasculonics, LLC
Indianapolis, United States Active
Researchers
- Principal investigator: Singh, Jaipal — Vasculonics, LLC
- Study coordinator: Singh, Jaipal
Related research
Other NIH-funded projects on the same topics.
-
Understanding how blood flow and pressure affect lungs in PAH
This grant studies how abnormal blood flow and pressure contribute to pulmonary arterial hypertension and how patient factors shape these effects, with the aim of guiding better therapies.
-
Asporin as a double-targeted therapy and biomarker for a serious artery disease
This project tests a protein called asporin as both a treatment and a biomarker for pulmonary arterial hypertension (PAH) to help people with this life-threatening condition.
-
Platelets and fibroblasts linked to energy use in a hard-to-treat blood vessel disease
A research team at the University of Pittsburgh is studying how platelet energy metabolism and fibroblast glutamine use interact in systemic sclerosis-related pulmonary arterial hypertension to improve diagnosis and treatment.
-
A biatrial dual‑lumen catheter to help the heart and lungs in pulmonary arterial hypertension
A new double‑lumen catheter is being developed to unload the right side of the heart and protect the lungs for people with pulmonary arterial hypertension.
-
Endothelial inflammation and Src kinase in early pulmonary arterial hypertension
Researchers are studying how inflammation in the lining of blood vessels and a protein called Src kinase contribute to early lung artery remodeling in people with mild PAH.
-
Cardiopulmonary chip model to study right heart disease from high blood pressure in the lungs
A tiny heart-lung chip is being developed to understand why the right side of the heart enlarges in people with pulmonary arterial hypertension and to test targeted treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.